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Background: High-quality, well-reported clinical practice guidelines (CPGs) and consensus statements
(CSs) underpinned by systematic reviews are needed. We appraised the quality and reporting of CPGs
and CSs for breast cancer (BC) treatment.
Methods: Following protocol registration (Prospero no: CRD42020164801), CPGs and CSs on BC treat-
ment were identified, without language restrictions, through a systematic search of bibliographic da-
tabases (MEDLINE, EMBASE, Web of Science, Scopus, CDSR) and online sources (12 guideline databases
and 51 professional society websites) from January 2017 to June 2020. Data were extracted in duplicate
assessing overall quality using AGREE II (% of maximum score) and reporting compliance using RIGHT (%
of total 35 items); reviewer agreement was 98% and 96% respectively.
Results: There were 59 relevant guidance documents (43 CPGs, 16 CSs), of which 20 used systematic
reviews for evidence synthesis. The median overall quality was 54.0% (IQR 35.9e74.3) and the median
overall reporting compliance was 60.9% (IQR 44.5e84.4). The correlation between quality and reporting
was 0.9. Compared to CSs, CPGs had better quality (55.4% vs 44.2%; p ¼ 0.032) and reporting (67.18% vs
44.5%; p ¼ 0.005). Compared to subjective methods of evidence analysis, guidance documents that used
systematic reviews had better quality (76.3% vs 51.4%; p ¼ 0.001) and reporting (87.1% vs 59.4%;
p ¼ 0.001).
Conclusion: The quality and reporting of CPGs and CSs in BC treatment were moderately strong. Sys-
tematic reviews should be used to improve the quality and reporting of CPGs and CSs.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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Breast cancer (BC) is the most frequent cancer in women (about
2 million new cases annually) accounting for 15% of global cancer
deaths (about 670,000 annually) [1e3]. Recent advances have
shown the potential to decrease morbidity andmortality [4e6], but
treatment success varies by region and type of hospital [7]. Clinical
practice guidelines (CPGs) and consensus statements (CSs) are
being promoted to harmonize the provision of effective health care
[8e11]. Rigorously developed CPGs and CSs should be well-
reported, deploying objective approaches for evidence analysis to
underpin the recommendations [10,12].
Previous evaluations of guidance in BC treatment have shown
that their quality can be heterogeneous [13e15]. However, these
reviews are non-recent, covering CPGs and CSs published between
2009 and 2017. They were limited in their searches and applied
languages restrictions to English only [13e15]. They have not had
the benefit of recent developments in the assessment of CPGs and
CSs [16,17]. It has been highlighted that quality and reporting are
two distinct aspects that need to be examined separately. The
former deals with issues of validity of the recommendations made
while that latter examines the thoroughness of the presentation of
the document prepared. In this regard, the thoroughness and
transparency of evidence synthesis is a key guideline feature [18].
As there is a requirement for periodic revisions, an updated and
comprehensive evaluation of recently published guidance docu-
ments is required [7].
In a systematic review, we exhaustively searched for recent
CPGs and CSs for BC treatment and appraised their quality and
reporting using validated tools, paying special attention to the
method used for evidence analysis.2. Methods
Following prospective registration (Prospero no:
CRD42020164801) a protocol-driven systematic review wasperformed using currently recommended methods for search and
assessment of guidelines and reported using PRISMA statement
(see Appendix 1) [1920].2.1. Data sources and searches
The initial search from 2017 onwards was conducted on April
4th, 2020. A search update was undertaken on June 15th, 2020. We
looked for online databases and guideline-specific databases
without language restrictions associating MeSH terms “breast
cancer”, “breast neoplasms”, “practice guidelines”, “guidelines”,
“consensus” and including word alternatives, covering the period
January 2017 to June 2020. We have also checked the specific
professional society’s websites looking for updated guidelines. We
decided to look for CPGs and CSs from 2017 onwards. The main
reason for focusing on this 3-year time window was that a sys-
tematic review of literature stated that most of the guidance
methodological handbooks for updating CPGs determined that the
time between updates should be two or three years [21]. By
excluding older guidance documents in which new knowledge for
good CPG methods has not been incorporated we were able to
review the most up-to-date literature. We looked for online data-
bases (MEDLINE, CDSR, Web of Science, EMBASE, Scopus, etc.), 51
websites of important professional societies, and 12 guidance-
specific databases (see Appendix 2). The main criterion for
searching the websites of professional societies was the contribu-
tion of their country of origin to global breast cancer’s scientific
production. We included professional societies in countries that
produce at least 0.5% of the documents appearing in Scopus about
Breast Cancer and Health Care (23,748 document results at July
10th, 2020). Finally, we searched the bibliographies of well-known
publications and the World Wide Web to include other important
documents in the review.
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CPGs and CSs about BC management produced by national or
international professional organizations and societies or govern-
mental agencies were included. Randomized controlled trials
(RCTs) and observational studies, narrative reviews, scientific re-
ports, discussion papers, conference abstracts and posters, CPGs
and CSs about screening and diagnosis, obsolete guidelines
replaced by updates from the same organization, and CPG and CSs
for education and information purpose only were excluded.
The eligibility of each of the abstracts and titles from the cita-
tions was considered independently by two reviewers (MMC and
LM), both breast cancer specialists. Full-text versions of potentially
relevant citations were obtained to confirm eligibility. A third
reviewer (MMD) helped to solve disagreements by consensus or
arbitration. Duplicate articles were identified and removed. Where
multiple versions were retrieved the most updated version of the
guidelines was included. Data were extracted from selected CPGs
and CSs in duplicate, independently.2.3. Assessment of quality and reporting
Two reviewers (MMC and LM) extracted data on a piloted pro-
forma to assess the quality and reporting of CPGs and CSs using two
validated appraisal tools, the AGREE II instrument and the RIGHT
statement (Appendix 3).16 [17] According to AGREE II quality was
the “reliability that potential development biases have been
appropriately addressed and recommendations are internally and
externally valid” [22]. Data were extracted for its 23 items ac-
cording to predefined criteria divided into six domains: scope and
purpose (items 1 to 3), stakeholder involvement (items 4 to 6), the
rigor of development (items 7 to 14), clarity and presentation
(items 15 to 17), applicability (items 18 to 21) and editorial inde-
pendence (items 22 and 23). A 7-point scale was used to score each
item (anchored between 1 or strongly disagree, i.e. when there was
no relevant information concerning the item, to 7 or strongly agree,
i.e. when the quality of reporting was exceptional, and the criteria
were fully met). The domain quality scores (0e100%) were calcu-
lated by summing up reviewers’ individual scores and scaling as a
percentage of the maximum possible score according to the for-
mula provided in the AGREE II manual averaging the scores of the
two reviewers [22]. To avoid major deviations in reviewers’ as-
sessments, we deployed discussion to reach consensus. In addition,
an overall guideline assessment was calculated using the mean
scores of the 6 standardized domain and a recommendation made:
a CPG or CS was “recommended” if the score >80% [23], “recom-
mended with modifications” if it was 50e80%, and “not recom-
mended” if <49% [24].
For reporting assessment data were extracted for the RIGHT [17]
statement’s 35 items divided into 7 domains: basic information
(items 1 to 4), background (items 5 to 9), evidence (items 10 to 12),
recommendations (items 13 to 15), review and quality assurance
(items 16 and 17), funding and declaration and management of
interests (items 18 and 19), and other information (items 20 to 22).
A numeric score of 1 (reported), 0.5 (partially reported), or 0 (un-
reported) was assigned to each item. Disagreements between two
reviewers in the scorewere discussed and unresolvedmatters were
addressed by an arbitrator (MMD). A percentage of the total was
calculated to obtain an overall reporting assessment and guidance
documents were classified as “well-reported” if the score was
>80%, “moderate-reported” if it was 50e80%, and “low-reported” if
<50% [24].2.4. Data analysis
Consistency between reviewers in data extraction was assessed
using the intraclass correlation coefficient (ICC), where excellent
reliability level was >0.90 [25]. A descriptive statistical analysis was
conducted for domains and overall scores. Kruskal-Wallis test was
used to compare scores and to evaluate factors that might affect the
quality and reporting of CPGs and CSs. All analyses were performed
using Stata 16. A value of p < 0.05 denoted statistical significance.
3. Results
3.1. Study selection
Of the 7430 potential citations identified, 7334 were from online
databases (MEDLINE, EMBASE, SCOPUS, Web of Science, Trip
database) and 96 were from additional sources (guideline specific
databases, professional societies, and the Word Wide Web). Of
them, 168 publications were found duplicated and 7205 did not
meet the selection criteria. A total of 59 documents (43 CPGs
[26e68] and 16 CSs 42e57 [69e84]) were identified for final
evaluation (Table 1). The flow diagram detailing the study selection
process is provided in Fig. 1. ICC for reviewer agreement was 0.98 in
AGREE II and 0.96 in RIGHT. The correlation between AGREE II and
RIGHT scores was r ¼ 0.90 (Appendix 4).
3.2. Quality assessment
The analysis of the documents with the AGREE II instrument
showed a wide overall score range (16e92%) (Fig. 2 and Appendix
5). The median overall quality was 54.0% (IQR 35.9e74.3). Only 13
(22%) of the CPGs or CSs were “recommended” as presented; the
rest were not (19 (32%) “not recommended”, 27 (46%) “recom-
mended with modifications”). Quality was heterogeneous in the
domains (Appendix 5). In Domains 1 (scope and purpose) and 4
(clarity of presentation) 39 (66%) and 30 (51%) CPGs and CSs
respectively scored >75%. In domain 5 (applicability) only 1 (2%)
CPG scored >75%. Domain 6 (Editorial independence) related to the
bias linked to conflict of interest, scored >75% in 34 (58%) CPGs but
it was 0% or almost 0% in five CPGs [26,40,57,63,64,66] and four CSs
[72,75,76,78,82]. The ASCO [43e50,52,53], Dutch [31] and Colom-
bian [58] CPGs had the highest quality scores (Fig. 2, Appendix 6).
For a better understanding of NICE guidelines, we studied the
“Developing NICE guidelines: the manual” [85]. This led to a slight
increase in the NICE CPGs scores, although it would be better if the
relevant manual content were included in each NICE CPG itself. It is
noteworthy that no specific methods are explained in the manual
and this made it difficult to analyze the quality of the guidances.
3.3. Reporting assessment
CPGs and CSs reporting was heterogeneous and had a wide
overall score range (16e89%) using the RIGHT statement (Fig. 3 and
Appendix 7). The median overall reporting compliance was 62.5%
(IQR 44.5e84.4). Only 5 (8%) of the CPGs and CSs were “well-re-
ported”, 31 (53%) were “moderate-reported” and 23 (39%) were
“low-reported”. Fig. 3 showed that reporting in domains was het-
erogeneous. The median of the domain scores was 67% (17e100%)
for domain 1 (basic information), 63% (0e100%) for domain 2
(background), 60% (0e100%) for domain 3 (evidence), 50% (0e86%)
for domain 4 (recommendations), 25% (0e75%) for domain 5 (re-
view and quality assurance), 0 (0e19%) for domain 6 (funding and
declaration and management of interests) and 50% (0e100%) for
domain 7 (other information). The ASCO [46,48e50] and Dutch [31]
CPGs had the highest reporting compliance (Appendix 8).
Table 1
Description of the CPGs and CSs (n ¼ 167) selected for the systematic review.












NHCPRC China 2018 CJCRCN 1 Not reported Not
reported
2 Early breast cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up(27)




3 ESO-ESMO 4th international consensus guidelines for breast








4 AGO Recommendations for the Diagnosis and Treatment of
Patients with Early Breast Cancer: Update 2019(29)
AGO Early BC
2019(29)
AGO Germany 2019 Breast Care 5 Review Not
reported
5 AGO Recommendations for the Diagnosis and Treatment of




AGO Germany 2018 Breast Care 5 Review Not
reported
6 Dutch breast reconstruction guideline(31) Dutch BCR(31) DPRS Netherlands 2017 JPRAS 1 Systematic
review
AGREE II
7 Cancer de mama/Breast Cancer(32) Fisterra BC(32) Fisterra Spain 2017 Not published 3 Not reported Not
reported
8 SEOM clinical guidelines in early-stage breast cancer(33) SEOM early-
stage(33)
















10 Abemaciclib with fulvestrant for treating hormone receptor-








11 Ribociclib with fulvestrant for treating hormone receptor-
positive, HER2-negativHER2-negative, advanced breast
cancer(36)












13 Breast reconstruction following prophylactic or therapeutic
mastectomy for breast cancer(38)
AHS reconstruction
BC(38)




14 Adjuvant systemic therapy for early stage (lymph node negative
and lymph node positive) breast cancer(39)




15 Performance and Practice Guidelines for the Use of Neoadjuvant








16 Evidence-Based Clinical Practice Guideline: Autologous Breast
Reconstruction with DIEP or Pedicled TRAM Abdominal Flaps(41)
ASPS DIEP &
TRAM(41)
ASPS USA 2017 PRS 2 Review Not
reported
17 Use of Endocrine Therapy for Breast Cancer Risk Reduction:
ASCO Clinical Practice Guideline Update(42)
ASCO Endocrine
therapy risk BC(42)




18 Postmastectomy Radiotherapy: An American Society of Clinical
Oncology, American Society for Radiation Oncology, and Society








19 Selection of Optimal Adjuvant Chemotherapy and Targeted








20 Systemic Therapy for Patients With Advanced Human Epidermal








21 Recommendations on Disease Management for Patients With
Advanced Human Epidermal Growth Factor Receptor 2ePositive








22 Integrative Therapies During and After Breast Cancer Treatment:
ASCO Endorsement of the SIO Clinical Practice Guideline(47)
ASCO BC
treatment(47)




23 Role of Bone-Modifying Agents in Metastatic Breast Cancer: An








24 Role of Patient and Disease Factors in Adjuvant Systemic Therapy
Decision Making for Early-Stage, Operable Breast Cancer:
American Society of Clinical Oncology Endorsement of Cancer
Care Ontario Guideline Recommendations(49)
ASCO factors in
early BC(49)




25 Use of Adjuvant Bisphosphonates and Other Bone-Modifying
Agents in Breast Cancer: A Cancer Care Ontario and American
Society of Clinical Oncology Clinical Practice Guideline(50)
ASCO use bone-
mod agents BC(50)




26 Use of Biomarkers to Guide Decisions on Adjuvant Systemic
Therapy for Women With Early-Stage Invasive Breast Cancer:
ASCO biomarkers in
early BC(51)
ASCO USA 2019 JCO 2 Review Not
reported
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Table 1 (continued )







American Society of Clinical Oncology Clinical Practice Guideline
Focused Update(51)
27 Use of Biomarkers to Guide Decisions on Systemic Therapy for
Women With Metastatic Breast Cancer: American Society of
Clinical Oncology Clinical Practice Guideline(52)
ASCO biomarkers in
MBC(52)




28 Adjuvant Endocrine Therapy for Women With Hormone









29 Optimal margins for breast-conserving surgery with whole-
breast irradiation in ductal carcinoma in situ: Results of the












30 Radiation therapy for the whole breast: Executive summary of
an American Society for Radiation Oncology (ASTRO) evidence-
based guideline(55)
ASTRO RT for whole
breast(55)




31 Breast Cancer. Version 3.2019(56) NCCN BC(56) NCCN USA 2019 JNCCN 4 Review Not
reported




33 Guía de practica clínica (GPC) para la deteccion temprana,
tratamiento integral, seguimiento y rehabilitacion del cancer de
mama(58)




34 Guía de Practica Clínica para el Tratamiento del Cancer de
Mama(59)
GPC Perú(59) IETSI Perú 2017 Not published 1 Systematic
review
AGREE II
35 The Screening, Diagnosis, Treatment, and Follow-Up of Breast
Cancer(60)




36 Cirugía de la Mama(61) AEC BC(61) AEC Spain 2017 Not published 2 Not reported Not
reported
37 Manual de Practica Clínica en Senología. 4a Edicion. 2019 (62) SESPM (62) SESPM Spain 2019 Not published 2 Not reported Not
reported
38 Linee guida: Neoplasie della mammela (63) CIS Neoplasia
mammella (63)
CIS Italy 2019 Not published 1 Not reported Not
reported




CIS Italy 2018 Not published 1 Not reported Not
reported
40 Recommandations du GEFPICS pour la prise en charge des
prelevements dans le cadre du traitement neoadjuvant du
cancer du sein (65)
GEFPICS Cancer du
sein (65)
GEFPICS France 2019 Annals of
Pathologie
1 Not reported Not
reported
41 Breast Cancer Clinical Guidelines(66) NCA BC(66) NCA UK 2019 Not published 1 Review Not
reported
42 The Japanese Breast Cancer Society Clinical Practice Guidelines
for systemic treatment of breast cancer, 2018 edition(67)
Japanese systemic
BC(67)




43 The Japanese Breast Cancer Society Clinical Practice Guidelines,








44 Consenso Mexicano sobre diagnostico y tratamiento del cancer
mamario (69)




45 Indian Solutions for Indian ProblemsdAssociation of Breast
Surgeons of India (ABSI) Practical Consensus Statement,
Recommendations, and Guidelines for the Treatment of Breast
Cancer in India(70)





46 4th ESOeESMO International Consensus Guidelines for
Advanced Breast Cancer (ABC 4) (71)






47 St. Gallen/Vienna 2019: A Brief Summary of the Consensus
Discussion about Escalation and De-Escalation of Primary Breast
Cancer Treatment(72)
St. Gallen 2019(72) St.
Gallen




48 Biomarkers in breast cancer: A consensus statement by the
Spanish Society of Medical Oncology and the Spanish Society of
Pathology(73)
SEOM & SEAP(73) SEOM &
SEAP
Spain 2017 CTO 1 Not reported Not
reported
49 Provincial consensus recommendations for adjuvant systemic
therapy for breast cancer(74)
CCM 2017(74) CCM Canada 2017 Not published 1 Systematic
review
AGREE II
50 Consensus Guideline on Accelerated Partial Breast Irradiation(75) ASBS RT(75) ASBS USA 2018 Not published 1 Review Not
reported
51 Consensus Guideline on the Use of Transcutaneous and
Percutaneous Ablation for the Treatment of Benign and
Malignant Tumors of the Breast(76)
ASBS ablation(76) ASBS USA 2018 Not published 1 Review Not
reported
52 Consensus Guideline on the Management of the Axilla in
Patients With Invasive/In-Situ Breast Cancer(77)
ASBS axilla(77) ASBS USA 2019 Not published 1 Review Not
reported
53 Consensus Guideline on Breast Cancer Lumpectomy Margins(78) ASBS margins(78) ASBS USA 2017 Not published 1 Review Not
reported








55 ESTRO-ACROP guideline: Interstitial multi-catheter breast
brachytherapy as Accelerated Partial Breast Irradiation alone or
ESTRO-ACROP
RT(80)




(continued on next page)
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as boost - GEC-ESTRO Breast Cancer Working Group practical
recommendations(80)
56 ESTRO ACROP consensus guideline for target volume delineation
in the setting of postmastectomy radiation therapy after








57 Recommendations for hypofractionated whole-breast
irradiation(82)






58 Treating HRþ/HER2- breast cancer in premenopausal Asian
women: Asian Breast Cancer Cooperative Group 2019 Consensus
and position on ovarian suppression(83)




59 International multidisciplinary expert panel consensus on breast
reconstruction and radiotherapy(84)




Fig. 1. The flow diagram detailing the study selection.
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As shown in Table 2 CPGs scored better than CSs regarding
quality (p ¼ 0.032) and reporting (p ¼ 0.005). CPGs from the USA
had a better score than Europe and the rest of the world (AGREE II
75.7% vs 45.1% vs 55.1, p ¼ 0.003; RIGHT 87.1% vs 55.5% vs 59.4,
p ¼ 0.015). The year of publication did not affect the quality
(p ¼ 0.791) or reporting (p ¼ 0.718). Compared to consecutive
updates of the CPG or CS, the second version when published
within the review period had better quality (p ¼ 0.001) and
reporting (p¼ 0.002). Compared to subjective methods of evidence
analysis, guidance documents that used systematic reviews had
better quality than consensus (76.3% vs 51.4%; p ¼ 0.001) and
reporting (87.1% vs 59.4%; p ¼ 0.001). CPGs and CSs published in a
journal showed better quality (66.5% vs 42.0%; p ¼ 0.001) and
reporting (65.6 vs 50.4; p ¼ 0.001) than those unpublished.4. Discussion
4.1. Main findings
The median overall quality and reporting of CPGs and CSs in BC
treatment were poor. Around two-thirds of all guidance documents
could not be recommended as written. Over three-quarters of all
guidance documents were not well-reported. Compared to CSs,
CPGs had better quality and reporting. Compared to subjective
methods of evidence analysis, CPGs and CSs using systematic re-
views and those published in a journal showed better quality and
reporting. Compared to updates, the first iteration CPGs and CSs
published within the review period had better quality and
reporting.
Fig. 2. AGREE II overall score of BC CPGs and CSs.
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Our review had a global perspective with a reasonable number
of CPGs and CSs identified using a comprehensive search without
language restrictions. English and Spanish are the most widely
spoken languages [86] and many of the Societies [32e34] present
versions in both English and Spanish. One strength of this review is
that the authors had command of both languages.
We had a prospective protocol using two well-developed
assessment tools, AGREE II instrument [16] and RIGHT statement
[17], for as complete an assessment as possible. To our knowledge,
an evaluation of guidance documents for BC treatment, using both
AGREE II and RIGHT tools, has not been reported previously. While
AGREE II instrument addresses different aspects of quality and
RIGHT statement is a reporting tool, some items partially overlap.
Our results suggest that reporting and quality are correlated. So
reporting CPGs or CSs according to the RIGHT recommendations
can lead to an increase in the AGREE scores, thus increasing the
quality of the guidances. One presumed limitation of this review
could be the subjective nature of data extraction concerning quality
and reporting items. We minimized this issue by using two expe-
rienced BC specialist clinicians who studied the assessment tool
manuals to create a mutual understanding of the scoring proced-
ures before duplicate data extraction. Where concerns about majordeviations arose, we used reviewer consensus backed by inde-
pendent arbitration. It was reassuring to note that the reviewer
agreement was excellent, with the ICC >95%.
Our main findings have some provisos in that the overall as-
sessments made might be limited because of the lack of clear rules
about the weighting of domains and items in the quality and
reporting scoring manuals [87]. Although RIGHT statement [17]
recommends against deriving a score from the checklist (the items
may not be equally weighted, and scores have been shown to be
problematic in research synthesis), we found it useful for
comparing CPGs and CSs. It also facilitated the comparison of
quality with reporting. The AGREE II Consortium [16] and RIGHT
team [17] have not preset the thresholds to differentiate between
high, moderate, and poor quality and reporting.We used previously
reported limits [23,24] to set the cut-offs for our analyses a priori.
We are, therefore, confident that our main findings concerning
poverty of guideline quality and reporting, and the negative impact
of lack of systematic review for evidence synthesis are robust.
These deficiencies merit urgent attention.
We studied articles published from 2017 onwards. So, we are
aware that guidance documents outside our time range from
reputable organizations would have been excluded. There was
heterogenicity amongst the guidelines included in the review. We
only included those guidelines that fulfilled the inclusion criteria.
Fig. 3. RIGHT overall score of BC CPGs and CSs.
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an important observation that merits consideration as a limitation
of the existing guidances. However, this type of heterogeneity may
be unavoidable as the guidances differ in their development,
structure, context, endpoint definitions, etc. according to target
users, both patients and clinicians [88].4.3. Implications
Our review and analysis highlighted that the quality and
reporting of the guidance documents in BC treatment has a wide
space for improvement. This is especially obvious in domains
concerning applicability and rigor of development in AGREE II. To
increase the general quality of CPGs and CSs, there is a necessity of
Table 2
Variables related to quality and reporting of CPGs and CSs.
AGREE II RIGHT
Variable Median IGQ Range p value Median IGQ Range p value
Type of document
CPGs 55.4% 44.6e76.5 67.18% 50.7e88.2
CSs 44.2% 32.2e60.9 p ¼ 0.032 44.5% 30.1e63.7 p ¼ 0.005
Country
USA 75.7% 48.9e76.8 p ¼ 0.003 87.1% 59.3e93.0 p ¼ 0.015
Europe 45.1% 34.4e53.9 55.5% 43.0e66.8
Other countries 55.1% 45.3e64.5 59.4% 44.5e76.5
Publication Year
2017 60.5% 46.4e75.4 71.9% 44.5e90.6
2018 48.3% 31.9e68.8 60.9% 35.9e76.6
2019 49.3% 37.0e75.2 58.2% 48.4e83.2
2020 53.9% 51.8e55.0 p ¼ 0.791 60.9% 59.4e65.6 p ¼ 0.718
Publication in a journal
Yes 66.5% 48.9e76.5 68.8% 59.4e89.8
No 42.0% 27.9e52.9 p ¼ 0.001 46.8% 37.5e52.4 p ¼ 0.001
Version number
1 45.1% 32.1e60.8 50.4% 30.1e64.8
2 76.0% 55.8e76.8 87.1% 62.5e91.8
3 or more 45.3% 33.3e68.8 p ¼ 0.001 65.6% 46.9e70.3 p ¼ 0.002
Evidence analysis
Consensus 51.4% 35.9e56.5 59.4% 42.2e67.2
Not reported 38.0% 15.9e45.6 50.0% 28.9e52.3
Review 42.0% 27.9e72.5 60.9% 30.5e78.1
Systematic review 76.3% 69.7e77.2 p ¼ 0.001 87.1% 75.0e92.9 p ¼ 0.001
Quality tool referral
Reported 70.3% 69.2e89.5 83.6% 76.6e97.7
Not reported 52.5% 35.7e73.7 p ¼ 0.073 60.9% 43.4e82.4 p ¼ 0.065
M. Maes-Carballo et al. / The Breast 53 (2020) 201e211 209improvement in considering the potential resource implications of
applying the recommendations, presenting monitoring and/or
auditing criterion, and providing a procedure for updating the
guideline (Appendix 9). In reporting using RIGHT, the domains in
need of closer attention are basic information, background, the
contrast of evidence of recommendations, and the declaration of
interest and funders. There is a need of amelioration in adding new
or key terms, a list of abbreviations and acronyms, in indicating
whether the draft guideline underwent independent review or
whether the guideline was subjected to a quality assurance process
(Appendix 10).
CPGs scored higher than CSs due to the fact their methods were
better developed, and they more often deployed systematic re-
views. Although the terms CPGs and CSs are often used inter-
changeably, they have differences that need to be highlighted. A
clinical practice guideline produces statements that are informed
by a systematic review of the evidence and an assessment of the
benefits and harms of alternative options. A consensus statement is
developed by an independent panel of experts, usually multidis-
ciplinary, convened to review the research literature in an
evidence-based manner for the purpose of advancing the under-
standing of an issuing procedure or method [89]. CSs are more
likely to be sponsored by a pharmaceutical company and to endorse
a specific product [89]. Unfortunately, transparency of document
development was generally poor in both types of documents, and
there was infrequent documentation of conflicts of interests,
sources of funding, how guideline groups were established and
who comprised their guideline development team. CSs are known
to score lower than CPGs for scores of the rigor of development and
editorial independence [89]. It is also necessary to highlight that
CSs are intended for controversial areas of breast management
(where the evidence is still incomplete), and the recommendations
are based on experts’ perspectives. This brings in the notion of
lower quality and broader risks of bias [89], which is relevant for
the guidance based on consensus.[27,28,81]It is interesting that only 2 CPGs referred to AGREE II in the
development of recommendations. The publication in a journal was
associated with better quality and reporting. This could be due to
reverse causality; however, every guidance should be submitted for
publication in a peer-review journal. Our observations are that
there is room for improvement that applies even to CPGs and CSs
with high scores as all have some deficiencies. There remains a
debate about cut-offs for defining acceptable scores and weighting
of the items and domains. These issues should be subject to future
research. In the current climate of formality and transparency, it
should not be admissible that some CPGs or CSs do not even meet
the basic quality and reporting criteria. These flaws will inevitably
reduce the possibility of providing the best care to patients.4.4. Conclusions
This systematic review found that CPGs and CSs for BC treat-
ment insufficiently followed quality and reporting assessment
tools. In the future, CPGs and CSs should take AGREE II and RIGHT
into account to produce high-quality guidance documents under-
pinned by systematic reviews to ensure that recommendations are
trustworthy. Focus on rigor in guidance development and practical
advice concerning the application of recommendations in clinical
setting is required for the implementation of evidence-based
medicine to improve health outcomes.Funding
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